For the Inventor, By the Inventor

Enter assignee name

Dublin, Ireland

Jazz Pharmaceuticals Ireland Limited

Calculating rank

USPTO Granted Patents = 41

EPO Patents = 9

Trademarks = 2

Forward Citations = 1,083

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Clark Patrick Allphin (11 out of 34 patents)

Mark Eller (8 out of 9 patents)

Katayoun Zomorodi (5 out of 18 patents)

4. Lawrence Patrick Carter (4 out of 7 patents)

5. Fionn Hurley (4 out of 8 patents)

6. Michael DesJardin (4 out of 8 patents)

7. Scott Bura (3 out of 4 patents)

8. Edwin Gerard Walsh (3 out of 7 patents)

9. Clifford David Jones (3 out of 16 patents)

10. Chiara Colletto (3 out of 3 patents)

11. Andrew Belfield (3 out of 3 patents)

12. Lars Friedrich (2 out of 2 patents)

13. Anne O'Donnell (2 out of 2 patents)

14. Tong Lin (2 out of 5 patents)

15. Yuan Lu (2 out of 9 patents)

Core Competencies:

Orexin Receptor Agonists

Hematological Disorders

RAS Inhibitors

Sodium Oxybate

Alcohol-Resistant Formulations

Fused Bicyclic Compounds

Gamma-Hydroxybutyrate

Solriamfetol Therapy

Modified L-Asparaginase

Cytokine Release Syndrome

Carbamoyl Phenylalaninol

Excessive Sleepiness

41 patents: Sort by Forward Citations

1. 12747252 - Orexin receptor agonists and uses thereof (2026-09-29),

2. 12642811 - Treatment of hematological disorders (2026-06-02),

3. 12612387 - RAS inhibitors and methods of using the same (2026-04-28),

4. 12582622 - Sodium oxybate to treat idiopathic hypersomnia (2026-03-24),

5. 12551540 - DOSING AND ADMINISTRATION OF RECOMBINANT L-ASPARAGINASE (2026-02-17),

6. 12440449 - Alcohol-resistant drug formulations (2025-10-14),

7. 12304912 - Fused bicyclic RAF inhibitors and methods for use thereof (2025-05-20),

8. 12138233 - Methods of treating idiopathic hypersomnia (2024-11-12),

9. 12121571 - Recombinant L-asparaginase (2024-10-22),

10. 11986446 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters (2024-05-21),

11. 11980636 - Treatment of hematological disorders (2024-05-14),

12. 11858930 - Fused bicyclic RAF inhibitors and methods for use thereof (2024-01-02),

13. 11802279 - Modified L-asparaginase (2023-10-31),

14. 11571440 - Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion (2023-02-07),

15. 11554102 - Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders (2023-01-17),

Company Overview

Jazz Pharmaceuticals Ireland Limited is a global biopharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs. The company specializes in areas such as sleep medicine, hematology, and oncology, leveraging advanced research and technology to create therapies that improve patient outcomes. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals operates with a commitment to enhancing the quality of life for patients worldwide through its dedicated research efforts and strategic partnerships.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

41 Patents

#46 in Dublin

#75 in Ireland

#16,731 in the World

Dublin, Ireland

Jazz Pharmaceuticals Ireland Limited

Forward Citations = 1,083

42 inventors:

Clark Patrick Allphin (11 out of 34 patents)

Mark Eller (8 out of 9 patents)

Katayoun Zomorodi (5 out of 18 patents)

4. Lawrence Patrick Carter (4 out of 7 patents)

5. Fionn Hurley (4 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Jazz Pharmaceuticals Ireland Limited. Retrieved from https://idiyas.com/company/jazz-pharmaceuticals-ireland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…